Estrella named Cynthia Pussinen CEO and board chair; she brings cell- and gene-therapy experience, and Cheng Liu remains president and becomes chief scientific officer. The filing adds pay terms and an approved 1,000,000-share option grant but reports no new drug or business results, so it does not clearly change Estrella's prospects.
Her experience in cell and gene therapy operations could help Estrella. Cheng Liu remains president and becomes chief scientific officer, preserving his role in the company. But the filing reports no new drug or business results. It also adds pay and a 1,000,000-share option grant, so these facts do not clearly change the company's prospects.
Follow Estrella Immunopharma, Inc. (ESLA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ESLA